APOLIPOPROTEIN B EXPRESSION STUDIES
载脂蛋白 B 表达研究
基本信息
- 批准号:2210793
- 负责人:
- 金额:$ 8.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1993
- 资助国家:美国
- 起止时间:1993-09-01 至 1998-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
As an internal medicine resident, I developed an interest in lipoprotein
metabolism and the pathogenesis of atherosclerotic disease. After a year
of clinical of clinical training in Endocrinology and Metabolism at UCSF,
I began basic research training in Dr. Stephen Young's laboratory at the
Gladstone Institute. During the past three years, my research has
focused on understanding several different aspects of apolipoprotein
(Apo) B genetics and metabolism: 1) the effect of liver transplantation
on apo B and apo E phenotype; 2) the expression of truncated apo B
species in hepatoma cells; 3) the investigation of a unique allele
causing hypobetalipoproteinemia, the apo B86 allele.
The apo B86 allele, which contains a one nucleotide deletion (frameshift)
in exon 26 of the apo B gene, results in the production of a truncated
apo B species, apo B86. Remarkably, genetic and biochemical evidence
from both affected family members and cell culture expression studies
indicate that the apo B86 allele yields a full-length apo B100 in
addition to apo B86. I have determined that the full-length protein is
produced from the apo B 86 allele as a result of reading frame
restoration, by a mechanism that appears to be unique in human genetics.
The first specific aim of this project is to further define this
mechanism for reading frame restoration. Site directed mutagenesis will
be used to delineate the exact DNA sequence requirements for reading
frame restoration. Mutant apo B constructs containing various DNA
sequence changes in the region of the apo B86 mutation will be expressed
in hepatoma cells. The apo B proteins (truncated vs. full-length)
produced by the transformed cell lines will be examined by immunoblot.
The mRNA from the transformed cell lines will be examined for evidence
of an error in transcription that would restore the proper reading frame.
Studies of the apo B86 protein suggest that apo B86 is incapable of
associating with apo (a) to form lipoprotein (a) [Lp(a)]. It is widely
assumed that apo B100 is linked to apo(a) by a disulfide linkage. Based
on our results with apo B86, we hypothesize that one (or more of the
carboxyl-terminal cysteines in apo B100 may be involved in forming a
disulfide bridge with apo(a). The second specific aim is to use site
directed mutagenesis and cell culture expression studies to evaluate the
importance of the four carboxyl-terminal cysteines of apo B100 in its
association with apo(a) to form Lp(a).
Cell culture expression studies of apo B100 have obvious limitations with
regard to investigating the role of apo B100 in the pathogenesis of
atherosclerosis. Therefore, I plan to develop an animal model in which
to test the hypothesis that overexpression of human apo B100 is
atherogenic. The third specific aim will be to overexpress human apo
B100 in transgenic mice. We plan to investigate the effects of
overexpression of human apo B100 in transgenic mice on lipid levels and
atherogenesis. In addition, we will develop an apo B86 transgenic mouse
as a model in which to study reading frame restoration in the apo B86
allele, and we propose to use transgenic mice to develop allotype
specific monoclonal antibodies to human apo B100.
作为居民,我对脂蛋白产生了兴趣
代谢和动脉粥样硬化疾病的发病机理。 一年后
UCSF内分泌和代谢临床培训的临床培训的临床培训,
我开始在Stephen Young博士实验室的基础研究培训
格拉德斯通研究所。 在过去的三年中,我的研究有
专注于理解载脂蛋白的几个不同方面
(APO)B遗传学和代谢:1)肝移植的影响
在apo b和apo e表型上; 2)截短的apo b的表达
肝癌细胞中的物种; 3)对独特等位基因的调查
引起低钙蛋白血症,Apo B86等位基因。
APO B86等位基因,其中包含一个核苷酸缺失(移料)
在Apo B基因的外显子26中,导致截短的产生
Apo B物种,Apo B86。 值得注意的是,遗传和生化证据
来自受影响的家庭成员和细胞培养表达研究
表示Apo B86等位基因在
除Apo B86。 我已经确定全长蛋白是
由于阅读框架,由Apo B 86等位基因产生
通过在人类遗传学中似乎是独一无二的机制恢复。
该项目的第一个具体目的是进一步定义
阅读框架修复的机制。 站点定向诱变将
用于描述阅读确切的DNA序列要求
框架修复。 包含各种DNA的突变Apo B构建体
APO B86突变区域的序列变化将表示
在肝癌细胞中。 Apo B蛋白(截短与全长)
由转化的细胞系产生的将由免疫印迹检查。
将检查来自转化细胞系的mRNA以获取证据
转录错误将恢复正确的阅读框。
对Apo B86蛋白的研究表明Apo B86无能力
与Apo(A)相关联,形成脂蛋白(a)[LP(a)]。 它是广泛的
假设APO B100通过二硫键链接到APO(A)。 基于
关于APO B86的结果,我们假设一个(或更多
Apo B100中的羧基末端半胱氨酸可能参与形成A
带有Apo(A)的二硫键。 第二个特定目的是使用网站
定向诱变和细胞培养表达研究以评估
Apo B100的四个羧基末端半胱氨酸的重要性
与Apo(a)相关联,形成LP(a)。
Apo B100的细胞培养表达研究具有明显的局限性
关于研究Apo B100在发病机理中的作用
动脉粥样硬化。 因此,我计划开发一种动物模型
测试人apo b100的过表达的假设为
动脉粥样硬化。 第三个具体目的是过表达人类apo
B100转基因小鼠。 我们计划调查
在脂质水平上的转基因小鼠中人apo B100的过表达,
动脉粥样硬化。 此外,我们将开发Apo B86转基因小鼠
作为研究Apo B86中阅读框架恢复的模型
等位基因,我们建议使用转基因小鼠开发异型
对人Apo B100的特异性单克隆抗体。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MACRAE F LINTON其他文献
MACRAE F LINTON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MACRAE F LINTON', 18)}}的其他基金
Macrophage SR-BI Regulates Autophagy, Angiogenin and tRNA-derived small RNAs
巨噬细胞 SR-BI 调节自噬、血管生成素和 tRNA 衍生的小 RNA
- 批准号:
9029105 - 财政年份:2016
- 资助金额:
$ 8.24万 - 项目类别:
Macrophage SR-BI Regulates Autophagy, Angiogenin and tRNA-derived small RNAs
巨噬细胞 SR-BI 调节自噬、血管生成素和 tRNA 衍生的小 RNA
- 批准号:
9195133 - 财政年份:2016
- 资助金额:
$ 8.24万 - 项目类别:
Dicarbonyl Scavengers to Improve HDL Function and Reduce Atherosclerosis in FH
二羰基清除剂可改善 FH 中的 HDL 功能并减少动脉粥样硬化
- 批准号:
10327715 - 财政年份:2014
- 资助金额:
$ 8.24万 - 项目类别:
相似国自然基金
冷刺激通过BAT中mTORC1-SREBP-PCSK9通路介导血脂代谢和动脉粥样硬化进程的机制研究
- 批准号:82170463
- 批准年份:2021
- 资助金额:55 万元
- 项目类别:面上项目
血脂成分与颈动脉粥样硬化发生发展的动态因果推断模型研究
- 批准号:82073668
- 批准年份:2020
- 资助金额:57 万元
- 项目类别:面上项目
血脂运输及稳态调控的特异分泌通路
- 批准号:91957119
- 批准年份:2019
- 资助金额:94.0 万元
- 项目类别:重大研究计划
GPR55介导溶血磷脂酰肌醇通过mtROS通路活化内皮细胞促进动脉粥样硬化机制研究
- 批准号:81870333
- 批准年份:2018
- 资助金额:57.0 万元
- 项目类别:面上项目
基于大规模队列揭示血脂基因MCU和EEPD1在糖脂代谢调节中的作用及功能研究
- 批准号:91857118
- 批准年份:2018
- 资助金额:78.0 万元
- 项目类别:重大研究计划
相似海外基金
Biogenesis and Catabolism of Atherogenic Lipoproteins
致动脉粥样硬化脂蛋白的生物发生和分解代谢
- 批准号:
10628985 - 财政年份:2023
- 资助金额:
$ 8.24万 - 项目类别:
Adipose MTP and FIT2 in the regulation of plasma lipids, obesity and atherosclerosis
脂肪MTP和FIT2在血脂、肥胖和动脉粥样硬化调节中的作用
- 批准号:
10628990 - 财政年份:2023
- 资助金额:
$ 8.24万 - 项目类别:
Cholesterol and inflammation Lowering via BEmpedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
HIV 试验中通过 BEmpedoic Acid(一种 ACL 抑制方案)降低胆固醇和炎症(CLEAR HIV 试验)
- 批准号:
10560409 - 财政年份:2022
- 资助金额:
$ 8.24万 - 项目类别:
Cholesterol and inflammation Lowering via BEmpedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
HIV 试验中通过 BEmpedoic Acid(一种 ACL 抑制方案)降低胆固醇和炎症(CLEAR HIV 试验)
- 批准号:
10677867 - 财政年份:2022
- 资助金额:
$ 8.24万 - 项目类别:
Lysophosphatidic Acid and Cardiovascular Disease Risk
溶血磷脂酸与心血管疾病风险
- 批准号:
10614416 - 财政年份:2021
- 资助金额:
$ 8.24万 - 项目类别: